CUPERTINO, Calif. – March 26, 2009 – Alliacense today announced that Hoffmann-La Roche Ltd. has purchased a Moore Microprocessor Patent™ (MMP) Portfolio license from the TPL Group. Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics.
“We are pleased with Roche’s decision to purchase an MMP Portfolio license”, said Andre-Pascal Chauvin, VP of Licensing in Alliacense’s European office. “Recently comforted by the positive decision of the German Federal Patent Court in Munich our MMP Portfolio is more than ever adding real value to market success, and enabling real growth.”
The sweeping scope of applications using MMP design techniques continues to encourage manufacturers of end user products from around the globe to become MMP licensees. Since January 2006, HP, Casio, Fujitsu, Sony, Nikon, Seiko Epson, Pentax, Olympus, Kenwood, Agilent, Lexmark, Schneider Electric, NEC Corporation, Funai Electric, SanDisk, Sharp Corporation, Nokia, Bull, LEGO, DMP Electronics, Denso Wave, TEAC, Daewoo Electronics, WMS, Lite-On IT, Alpine, Verigy, Humax, Psion, Tokyo Electron, DIRECTV, Mattel, AMO, Citizen, Gerber Scientific, Emerson Radio, RIM, Onkyo, Hoya, Robert Bosch, Audiovox, Rockwell Automation and Asustek, have all purchased MMP Portfolio licenses.
About the MMP Portfolio
The Moore Microprocessor Patent Portfolio contains intellectual property that is jointly owned by the privately-held TPL Group and publicly-held Patriot Scientific Corporation (OTCBB: PTSC). The MMP Portfolio includes seven U.S. patents as well as their European and Japanese counterparts. It is widely recognized that the MMP Portfolio protects fundamental technology used in microprocessors, microcontrollers, digital signal processors (DSPs), embedded processors and system-on-chip (SoC) devices. Manufacturers of microprocessor-based products can learn more about how to participate in the MMP Portfolio Licensing Program by contacting: email@example.com.
Alliacense is a TPL Group Enterprise executing best-in-class design and implementation of Intellectual Property (IP) licensing programs. As a cadre of IP licensing strategists, technology experts, and experienced business development/management executives, Alliacense focuses on expanding the awareness and value of TPL’s IP portfolios. Founded in 1988, The TPL Group has emerged as a coalition of high technology enterprises involved in the development, management and commercialization of proprietary product technologies as well as the design, manufacture and sales of proprietary products based on those technologies and corresponding IP assets. For more information, visit www.alliacense.com.
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2008 sales by the Pharmaceuticals Division totalled 36.0 billion Swiss francs, and the Diagnostics Division posted sales of 9.7 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested nearly 9 billion Swiss francs in R&D in 2008. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at www.roche.com.
# # #
Alliacense and Moore Microprocessor Patent (MMP) are trademarks of Technology Properties Limited (TPL). All other trademarks belong to their respective owners.